Multidisciplinary treatment planning for older people with lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm interventional program at West China Hospital enrolling 2,000 patients aged 60–90 with newly diagnosed non-small cell or small cell lung cancer. Each patient receives a comprehensive geriatric assessment and an individualized treatment plan created by a multidisciplinary team including thoracic surgeons, geriatricians, oncologists, pulmonologists, rehabilitation therapists, and radiologists. Treatment options span surgery, ablation, stereotactic body radiotherapy, neoadjuvant immunochemotherapy, targeted therapy, and best supportive care, and outcomes will be compared to a historical control cohort using propensity score matching. The primary outcome is 3-year progression-free survival, with secondary endpoints of overall survival, objective response rate, quality of life, and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 60 to 90 years.
2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
3. Clinical stage I-IV (according to the 9th edition of the IASLC TNM staging system).
4. ECOG Performance Status 0-2.
5. Estimated life expectancy ≥ 3 months.
6. Able to tolerate baseline examinations (including CT, MRI, pulmonary function tests) and at least one planned treatment modality (surgery, ablation, SBRT, etc.) as assessed by the investigator.
7. Patients or their legal representatives provide written informed consent and commit to completing the full follow-up schedule (including questionnaires and functional assessments).
8. Other conditions deemed suitable by the investigator.

Exclusion Criteria:

1. History of another active primary malignancy within the previous 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ, or another malignancy considered unlikely to affect the study outcomes.
2. Lung cancer cannot be confirmed by histologic or cytologic examination.
3. A medical emergency requiring immediate treatment that precludes completion of the baseline study procedures and MDT review before treatment initiation.
4. Cognitive or communication impairment that prevents completion of the core study procedures when no legally authorized representative or appropriate proxy assistance is available.
5. A contraindication to all clinically acceptable methods required for the core study-specific baseline assessment, with no suitable alternative assessment available.
6. Concurrent participation in another interventional study that mandates a treatment strategy incompatible with the CGA-informed MDT care pathway.
7. Any condition that makes the study-specific assessment procedures unsafe, provided that the reason for exclusion is documented by the investigator.

Where it's running

• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Yu Tong, Master's degree
• Email: tongyu0218@163.com
• Phone: 18180182544

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ALG Lung Cancer Registry (SAFRO2202)

  This registry will collect medical information from adults in Algeria who have been diagnosed with any type of lung cancer to see patterns in diagnosis, treatment, and outcomes.

  Recruiting at 21 sites Société Algérienne de Formation et de Recherche en Oncologie · Algiers, Algiers Province and 20 other locations · NCT07161882

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• Ongoing collection of blood and tumor samples from people with lung cancer

  Collect and store blood and tumor samples over time from adults with newly diagnosed or metastatic lung cancer to build a real-world biobank for research.

  Recruiting Nantes University Hospital · Angers and 3 other locations · NCT06481813

• Testing a new drug for adults with advanced solid tumors

  This study is testing a new drug for adults with advanced solid tumors that haven't responded to other treatments to see if it can help them.

  Recruiting at 43 sites Phase 1 Seagen Inc. · Phoenix, Arizona and 47 other locations · NCT06131840

• AI-assisted longitudinal CT to guide indeterminate lung nodules

  This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895277

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.